Details for New Drug Application (NDA): 020474

✉ Email this page to a colleague

NDA 020474 describes VEXOL, which is a drug marketed by Harrow Eye and is included in one NDA. Additional details are available on the VEXOL profile page.

The generic ingredient in VEXOL is rimexolone. There is one drug master file entry for this compound. Additional details are available on the rimexolone profile page.

Summary for 020474

Tradename:	VEXOL
Applicant:	Harrow Eye
Ingredient:	rimexolone
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SUSPENSION/DROPS;OPHTHALMIC			Strength	1%
Approval Date:	Dec 30, 1994	TE:		RLD:	No

Expired US Patents for NDA 020474

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	VEXOL	rimexolone	SUSPENSION/DROPS;OPHTHALMIC	020474-001	Dec 30, 1994	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.